Usefulness of SynCAM3 and cyclin D1 immunohistochemistry in distinguishing superficial CD34-positive fibroblastic tumor from its histological mimics

• Published in: Medical molecular morphology Vol. 56; no. 1; pp. 69 - 77
• Main Authors: Sugita, Shintaro, Takenami, Tomoko, Kido, Tomomi, Aoyama, Tomoyuki, Hosaka, Michiko, Segawa, Keiko, Sugawara, Taro, Fujita, Hiromi, Murahashi, Yasutaka, Emori, Makoto, Tsuyuki, Atsushi, Hasegawa, Tadashi
• Format: Journal Article
• Language: English
• Published: Singapore Springer Nature Singapore 01.03.2023; Springer Nature B.V
• Subjects: Anatomy; Biomarkers, Tumor; CD34 antigen; Cyclin D1; Cytokeratin; Differential diagnosis; Fibrosarcoma - pathology; Fluorescence in situ hybridization; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Keratins; Malignancy; Medicine; Medicine & Public Health; Molecular Medicine; Original Paper; Pathology; Sarcoma; Skin Neoplasms; Soft Tissue Neoplasms - diagnosis; Soft Tissue Neoplasms - pathology; Tumor cells; Immunohistochemistry; SynCAM3; Myxoinflammatory fibroblastic sarcoma; Fluorescence in situ hybridization; Superficial CD34-positive fibroblastic tumor; Myxofibrosarcoma; Cyclin D1; PRDM10; Undifferentiated pleomorphic sarcoma
• ISSN: 1860-1480; 1860-1499
• DOI: 10.1007/s00795-022-00341-w

Superficial CD34-positive fibroblastic tumor (SCPFT) is a fibroblastic/myofibroblastic soft tissue tumor of rarely metastasizing intermediate malignancy. Some recent studies have described a relationship between SCPFT and PRDM10 -rearranged soft tissue tumor (PRT) based on SynCAM3 and PRDM10 expression on immunohistochemistry. We performed CD34, cytokeratin AE1/AE3, SynCAM3, and PRDM10 immunohistochemistry in SCPFT and its histological mimics, including myxoinflammatory fibroblastic sarcoma (MIFS), superficially localized myxofibrosarcoma (MFS), and undifferentiated pleomorphic sarcoma. We also examined cyclin D1 expression because it is expressed in MIFS and MFS. We conducted fluorescence in situ hybridization (FISH) of PRDM10 rearrangement in SCPFT cases. On immunohistochemistry, only SCPFT showed strong and diffuse SynCAM3 expression. SCPFT also exhibited strong nuclear and weak cytoplasmic cyclin D1 expression, which was similar to that observed in MIFS. Two of five SCPFT cases exhibited nuclear PRDM10 expression. FISH revealed PRDM10 split signals in 44% and 24% of tumor cells in two SCPFT cases showing nuclear PRDM10 expression on immunohistochemistry, respectively. A minority of non-SCPFT cases showed focal SynCAM3 expression, but a combination of SynCAM3 and cyclin D1 in addition to CD34 and cytokeratin AE1/AE3 may be useful for the differential diagnosis of SCPFT and its histological mimics.